Tecentriq (atezolizumab)

pCPA File Number: 22000
Negotiation Status:
Under consideration for negotiation
Indication(s):
Indicated as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA (per the American Joint Committee on Cancer [AJCC], 7th edition) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs) and do not have EGFR or ALK genomic tumour aberrations
Sponsor/Manufacturer:
Hoffmann-La Roche
CADTH Project Number:
PC0269
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable